ARO-INHBE begins Phase 1/2a trial for safety, PK, and PD in obesity and T2DM
Background
Obesity and type 2 diabetes mellitus (T2DM) represent significant global health challenges, driving increased risks of cardiovascular disease, metabolic dysfunction, and reduced quality of life. Current therapeutic strategies, including lifestyle interventions and pharmacotherapies like GLP-1 receptor agonists (GLP-1 RAs), have shown considerable success in weight management and glycemic control. However, limitations such as side effects, varying patient responses, and the need for diverse mechanistic approaches highlight an unmet need for novel treatments. Exploring new pathways beyond established targets is crucial to offer broader therapeutic options and improve outcomes for the millions affected by these chronic conditions. This trial investigates a new compound, ARO-INHBE, for these critical metabolic diseases.
Study Design
This is a Phase 1/2a, randomized, quadruple-blind, placebo- and active-controlled dose-escalation study. It will enroll an estimated 180 adult participants with obesity, both with and without type 2 diabetes mellitus (T2DM). The study will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple subcutaneous (SC) doses of ARO-INHBE. Participants will receive either ARO-INHBE (SC injection), Placebo (SC injection), or an active comparator, Tirzepatide (SC injection). The trial is designed to characterize the compound's profile across different dose levels and patient populations.
Why It Matters
If successful, the ARO-INHBE trial could introduce a novel therapeutic mechanism for obesity and type 2 diabetes mellitus (T2DM), potentially offering an alternative or complementary option to existing GLP-1 receptor agonists. A new mechanism could address non-responders to current therapies, improve side effect profiles, or provide enhanced metabolic benefits. The inclusion of a tirzepatide comparator arm is particularly significant, allowing for direct comparison against a highly effective current standard of care. Positive results from this early-phase study would pave the way for larger trials, accelerating the development of a potentially impactful new treatment to improve weight management, glycemic control, and overall metabolic health for a broad patient population.